The following personnel contributed to writing and/or approving this protocol: Sign00.:_,,/ 7-:d Date: /14,{l v(f? / }cJ/8 JohJYif Lee, MD Vice President Adult Medical Affairs, NantKwest Inc. 9920 Jefferson Blvd Culver City, CA 90232 Email: John .Lee@Nantkwest.com Cell Phone:+ 1-605-610-6391 Confidential and Proprietary 155 NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 3 Confidential and Proprietary 1 TITLE PAGE NANT TRIPLE NEGATIVE BREAST CANCER (TNBC) VACCINE: MOLECULARLY INFORMED INTEGRATED IMMUNOTHERAPY COMBINING INNATE HIGH -AFFINITY NATURAL KILLER (ha NK) CELL THERAPY WITH ADENOVIRAL AND YEAST - BASED VACCINES TO INDUCE T -CELL RESPONSES IN SUBJECTS WITH TNBC WHO HAVE PROGRESSED ON OR AFTER STANDARD -OF-CARE THERAPY Study Number: QUILT -3.067 IND Sponsor: NantKwest, Inc. 9920 Jefferson Blvd Culver City, CA 90232 Sponsor Contact: (For medical questions/emergencies) John H.